Charles River Laboratories – Non-animal In Vitro Toxicology Efforts & Q2 2022 Company Update

  • Credit
  • Healthcare
  • North America


Former director at Charles River Laboratories International Inc


  • Charles River’s (NYSE: CRL) consolidation and investment strategy into niche analytical groups including transition to non-animal in vitro and on-a-chip models
  • Charles River’s quality and reputation among regulatory agencies and potential effects of recent FDA and EPA (Environmental Protection Agency) announcements on animal testing
  • Charles River’s service breakdown and assessment of the following segments – DSA and RMS – touching upon their strengths, gaps and positioning within each segment
  • Trickle-down effect of recent biotech funding slowdown and inflation on Charles River and additional supply chain issues
  • Competitive positioning and one-stop-shop system benefits
  • Q3 2022 outlook and future M&A and geographical expansion strategies to bolster growth


Gain access to Premium Content

Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.

    One week, unlimited access to over 40,000 transcripts
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited